Table 4 Association between immunostaining and Fuhrman grade and stage.
From: Evaluation of neuroendocrine markers in renal cell carcinoma
| Â | Â | Immunostaining | Â | |
|---|---|---|---|---|
Fuhrman grade or stage | Marker | immunonegative, n (%) | immunopositive, n (%) | p-value |
grade I | serotonin | 5 (100) | 0 (0) | 0.2 |
grade II | Â | 75 (95) | 4 (5) | Â |
grade III | Â | 31 (84) | 6 (16) | Â |
grade IV | Â | 20 (91) | 2 (9) | Â |
stage I | serotonin | 60 (91) | 6 (9) | 0.6 |
stage II | Â | 9 (90) | 1 (10) | Â |
stage III | Â | 45 (90) | 5 (10) | Â |
stage IV | Â | 19 (100) | 0 (0) | Â |
grade I | CD56 | 5 (100) | 0 (0) | 0.7 |
grade II | Â | 65 (83) | 13 (17) | Â |
grade III | Â | 29 (78) | 8 (22) | Â |
grade IV | Â | 17 (77) | 5 (23) | Â |
stage I | CD56 | 59 (88) | 8 (12) | 0.2 |
stage II | Â | 7 (70) | 3 (30) | Â |
stage III | Â | 38 (78) | 11 (22) | Â |
stage IV | Â | 14 (78) | 4 (22) | Â |
grade I | NSE | 0 (0) | 5 (100) | 0.1 |
grade II | Â | 41 (52) | 38 (48) | Â |
grade III | Â | 22 (56) | 17 (44) | Â |
grade IV | Â | 11 (55) | 9 (45) | Â |
stage I | NSE | 35 (52) | 32 (48) | 0.6 |
stage II | Â | 6 (55) | 5 (45) | Â |
stage III | Â | 28 (57) | 21 (43) | Â |
stage IV | Â | 7 (39) | 11 (61) | Â |